Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events

scientific article published on 01 October 2003

Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ART.11277
P698PubMed publication ID14558081

P2093author name stringStephen A Paget
Yusuf Yazici
Doruk Erkan
P433issue10
P304page(s)2769-2772
P577publication date2003-10-01
P1433published inArthritis and RheumatismQ23929027
P1476titleMonitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events
P478volume48

Reverse relations

cites work (P2860)
Q24817087Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
Q35165677Are rheumatologists' treatment decisions influenced by patients' age?
Q35555217Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.
Q46598057Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept
Q37807149Surveillance for and Prevention of Nonrheumatologic Diseases in the Patient with a Rheumatologic Diagnosis

Search more.